

Title (en)
POLYAMINE TREATMENT OF NEUROLOGICAL DISORDERS

Title (de)
POLYAMIN-BEHANDLUNG VON NEUROLOGISCHEN STÖRUNGEN

Title (fr)
TRAITEMENT DE TROUBLES NEUROLOGIQUES AU MOYEN DE POLYAMINES

Publication
EP 1017275 A4 20021218 (EN)

Application
EP 98944471 A 19980821

Priority
• US 9817301 W 19980821
• US 91566097 A 19970821

Abstract (en)
[origin: WO9908519A1] 2,3,2 Tetramine (3,7-diazanonane-1,9-diamine) is propounded for the treatment of Parkinson's Disease and dementias characterized by mitochondrial damage in view of this compound's ability to completely neutralize the dopamine-depriving effect of MPTP in laboratory animals up to 12 hours post MPTP injection, and to retain partial protection at suboptimal tissue levels for up to 36 hours. The effect of injecting combinations of MPTP and/or reducing agents and/or xenobiotics and/or depigmenting agents on Dopamine, Norepinephrine, Serotonin and Epinephrine levels demonstrated that MPTP and MPP+ act as reducing agents that mobilize copper and calcium, and sequester iron, and that the vulnerability of dopamine to these types of neurotoxins and to xenobiotics and metals can be corrected by administration of 2,3,2 tetramine that appears to redistribute metals between diverse storage pools and free metals in cytosol and regulate receptor mediated events, among other antidotal effects analogous to those of some of the endogenous polyamines.

IPC 1-7
A01N 33/02

IPC 8 full level
A61K 31/495 (2006.01); **A61K 31/13** (2006.01); **A61K 31/132** (2006.01); **A61K 31/395** (2006.01); **A61P 25/00** (2006.01); **A61P 25/16** (2006.01); **A61P 25/28** (2006.01); **A61P 43/00** (2006.01)

CPC (source: EP US)
A61K 31/13 (2013.01 - EP US); **A61K 31/395** (2013.01 - EP US); **A61P 25/00** (2017.12 - EP); **A61P 25/16** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 43/00** (2017.12 - EP)

Citation (search report)
• [A] US 5494935 A 19960227 - MILLER SCOTT C [US], et al
• [A] US 4323558 A 19820406 - NELSON ERIC L
• [A] PATENT ABSTRACTS OF JAPAN vol. 1995, no. 08 29 September 1995 (1995-09-29)
• [A] PALL H S ET AL: "RAISED CEREBROSPINAL-FLUID COPPER CONCENTRATION IN PARKINSON'S DISEASE", LANCET THE, LANCET LIMITED, LONDON, GB, 1 August 1987 (1987-08-01), pages 238 - 241, XP002914997, ISSN: 0140-6736
• [A] BORTHWICK T R ET AL: "A COMPARISON OF CUPRURETIC RESPONSES TO VARIOUS TETRAMINES AND D- PENICILLAMINE", JOURNAL OF LABORATORY AND CLINICAL MEDICINE, ST. LOUIS, MO, US, vol. 95, no. 4, April 1980 (1980-04-01), pages 575 - 580, XP002914996, ISSN: 0022-2143
• [A] SEIDL R ET AL: "POLYAMINES IN FRONTAL CORTEX OF PATIENTS WITH DOWN SYNDROME AND ALZHEIMER DISEASE", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 206, 1996, pages 193 - 195, XP002914995, ISSN: 0304-3940
• [A] BARBEAU A ET AL: "COMPARATIVE BEHAVIORAL, BIOCHEMICAL AND PIGMENTARY EFFECTS OF MPTP, MPP+ AND PARAQUAT IN RANA PIPIENS", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 37, no. 16, 1985, pages 1529 - 1538, XP002914994, ISSN: 0024-3205
• See references of WO 9908519A1

Cited by
WO2014085830A3

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 9908519 A1 19990225; AT E449536 T1 20091215; AU 737484 B2 20010823; AU 9200698 A 19990308; CA 2339782 A1 19990225; CA 2339782 C 20050614; CN 1216599 C 20050831; CN 1271250 A 20001025; DE 69841318 D1 20100107; EA 004400 B1 20040429; EA 200000244 A1 20001030; EP 1017275 A1 20000712; EP 1017275 A4 20021218; EP 1017275 B1 20091125; HK 1029494 A1 20010406; JP 2001515012 A 20010918; US 5906996 A 19990525

DOCDB simple family (application)
US 9817301 W 19980821; AT 98944471 T 19980821; AU 9200698 A 19980821; CA 2339782 A 19980821; CN 98809401 A 19980821; DE 69841318 T 19980821; EA 200000244 A 19980821; EP 98944471 A 19980821; HK 01100362 A 20010112; JP 2000509279 A 19980821; US 91566097 A 19970821